Celcuity, Inc. (NASDAQ:CELC) Given Consensus Rating of "Buy" by Analysts

Celcuity, Inc. (NASDAQ:CELC - Get Free Report) has earned a consensus rating of "Buy" from the six analysts that are currently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $28.40.

CELC has been the subject of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $27.00 target price on shares of Celcuity in a report on Monday, May 19th. Needham & Company LLC reiterated a "buy" rating and issued a $29.00 price target on shares of Celcuity in a research note on Monday, June 30th. Finally, Stifel Nicolaus assumed coverage on shares of Celcuity in a research note on Tuesday, July 1st. They issued a "buy" rating and a $30.00 price target for the company.

Celcuity Stock Up 0.4%

Celcuity stock traded up $0.06 during trading hours on Tuesday, hitting $13.40. The stock had a trading volume of 149,739 shares, compared to its average volume of 277,741. The company has a quick ratio of 6.61, a current ratio of 6.61 and a debt-to-equity ratio of 1.14. The stock has a market capitalization of $507.46 million, a P/E ratio of -4.42 and a beta of 0.45. Celcuity has a 12-month low of $7.58 and a 12-month high of $19.77. The stock's 50-day moving average price is $11.56 and its 200-day moving average price is $11.26.

Celcuity (NASDAQ:CELC - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $0.09. Equities research analysts anticipate that Celcuity will post -2.62 EPS for the current fiscal year.

Institutional Trading of Celcuity

Large investors have recently made changes to their positions in the stock. GAMMA Investing LLC grew its stake in shares of Celcuity by 1,237.4% in the first quarter. GAMMA Investing LLC now owns 1,324 shares of the company's stock worth $131,000 after acquiring an additional 1,225 shares during the period. Summit Investment Advisors Inc. grew its position in Celcuity by 49.5% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company's stock valued at $45,000 after buying an additional 1,132 shares during the period. Aquatic Capital Management LLC bought a new stake in Celcuity during the fourth quarter valued at approximately $50,000. Focus Financial Network Inc. bought a new stake in Celcuity during the first quarter valued at approximately $108,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Celcuity during the fourth quarter valued at approximately $142,000. 63.33% of the stock is currently owned by institutional investors.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.